Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ifosfamide
Drug ID BADD_D01133
Description Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Indications and Usage Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
Marketing Status approved
ATC Code L01AA06
DrugBank ID DB01181
KEGG ID D00343
MeSH ID D007069
PubChem ID 3690
TTD Drug ID D02TLO
NDC Product Code 10019-925; 57884-0006; 63323-142; 0143-9531; 0338-3991; 15308-0411; 0338-3993; 65124-0001; 0143-9530; 10019-926; 10019-927; 10019-929
UNII UM20QQM95Y
Synonyms Ifosfamide | Isofosfamide | Isophosphamide | Iphosphamide | Iso-Endoxan | Iso Endoxan | Holoxan | NSC-109,724 | NSC 109,724 | NSC109,724 | NSC-109724 | NSC 109724 | NSC109724 | Asta Z 4942
Chemical Information
Molecular Formula C7H15Cl2N2O2P
CAS Registry Number 3778-73-2
SMILES C1CN(P(=O)(OC1)NCCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Enuresis19.07.04.001; 20.02.02.003---
Erythema23.03.06.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Extrapyramidal disorder17.01.02.0070.000168%
Extravasation08.01.03.008---
Eye disorder06.08.03.001---
Eye irritation06.04.05.003---
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.0030.000112%-
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.0040.000112%
Fanconi syndrome03.06.01.001; 14.01.01.011; 20.05.03.009---
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.0040.001119%
Feeling abnormal08.01.09.014---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Fungal infection11.03.05.001---
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.000112%
Gastrointestinal disorder07.11.01.0010.000224%-
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009---
Gastrointestinal pain07.01.05.005--
Haematemesis07.12.02.002; 24.07.02.011---
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.0470.000112%
Haemoglobin13.01.05.018---
Haemolytic anaemia01.06.03.002---
Haemolytic uraemic syndrome01.06.02.001; 20.01.03.011--
Haemoptysis02.11.04.009; 22.02.03.004; 24.07.01.0060.000112%-
Hallucination19.10.04.003--
Hallucination, auditory19.10.04.004---
Hallucination, visual19.10.04.0070.000168%-
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001---
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene